ASCO Report：2025 Biomedtracker Datamonitor Healthcare Post

SummaryThe2025Annual Meetingof theAmericanSocietyof ClinicalOncology(ASCO)washeldinChicagofromMay30th-June 3rd, 2025. This post-meeting report features commentary from our analysts on key presentations at theconference as well as a compilation of all data events added toBiomedtracker in conjunction with the meeting.Asareminder,ourASCOcoveragewillcontinuethroughouttheconferenceandbeyond.Ourcoveragewillinclude:•June16–Post-ASCOWebinar•June20–Post-ASCOPodcastAbouttheAuthorBiomedtrackeris anindependent research service that offers proprietary clinical assessments and patient-basedrevenue forecasts of developmental drugs within a comprehensive and intuitive drug information database. Clientsfrom the pharmaceutical, biotech, and investment industries rely on Biomedtracker forits insight on the likelihood ofapproval, commercialpotential,andfuturedataandregulatorycatalystsfordrugswithinthecompetitivelandscapeofevery important disease and indication. Over the last several years, Biomedtracker has become the leader inproviding objective information alongside evidence based clinical assessments and investment research on pipelinedrugs worldwide. For more information on getting direct access to Biomedtracker, please emailclientservices@evaluate.com.DisclaimerCopyright©2025Evaluate,aNorstellacompanyThis report is published by Evaluate (thePublisher). This report contains information from reputable sources andalthough reasonable efforts have been made to publish accurate information, you assume sole responsibility for theselection, suitabilityanduseof thisreportandacknowledgethat thePublishermakesnowarranties(either expressorimplied) as to, nor accepts liabilityfor, the accuracy or fitness for a particular purpose of the information or advicecontained herein. The Publisher wishes to make it clear that anyviews or opinions expressed in this report byindividual authors or contributors are their personal views and opinions and do not necessarily reflect theviews/opinions of the Publisher. Copyright ©️2025Evaluate,aNorstellacompany(Unauthorizedphotocopyingprohibited) 3Copyright©2025Evaluate,aNorstellacompany(Unauthorizedphotocopyingprohibited)LisaftoclaxforAcuteMyelogenousLeukemia(AML)..................................................................................................6ZiftomenibforAcuteMyelogenousLeukemia(AML)..................................................................................................9Azacitidine forAcuteMyelogenousLeukemia(AML)................................................................................................12InqoviforAcuteMyelogenousLeukemia(AML).......................................................................................................15PadcevforBladderCancer........................................................................................................................................18OpdivoforBladderCancer........................................................................................................................................21YervoyforBladderCancer........................................................................................................................................24TrodelvyforBladderCancer......................................................................................................................................27KeytrudaforBladderCancer.....................................................................................................................................30BavencioforBladderCancer.....................................................................................................................................33TookadforBladderCancer........................................................................................................................................36SasanlimabforBladderCancer.................................................................................................................................39INB-200forBrainCancer(MalignantGlioma;AAandglioblastoma(GBM)).............................................................42ScemblixforChronicMyelogenousLeukemia(CML)................................................................................................45AzacitidineforChronicMyelomonocyticLeukemia(CMML).....................................................................................47TecentriqforColorectalCancer(CRC).......................................................................................................................50JMT101forColorectalCancer(CRC).........................................................................................................................53StivargaforColorectalCancer(CRC).........................................................................................................................55OpdivoforColorectalCancer(CRC)....................................................................................................